Eva Mulder (Trophic Communications GmbH)

Mulder, Eva (Trophic Commincations 202005– Account Director before Uniqure)

	Organisation	Trophic Communications GmbH
	Former/major organisation	Uniqure N.V. (Nasdaq: QURE)
	Group	Uniqure (Group)
	Product	public relations / investor relations / marcom (services)
	Product 2	LIFE SCIENCES

Record changed: 2024-07-17

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Eva Mulder

[1] Immatics N.V.. (10/24/23). "Press Release: Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy". Houston, TX & Tübingen....
[2] Immatics N.V.. (10/10/22). "Press Release: Immatics Announces $110 Million Underwritten Offering of Ordinary Shares". Houston, TX & Tübingen....
[3] Immatics N.V.. (10/10/22). "Press Release: Immatics Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME". Houston, TX & Tübingen....
[4] Immatics N.V.. (9/10/22). "Press Release: Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022". Houston, TX & Tübingen....
[5] Uniqure N.V.. (9/5/19). "Press Release: Uniqure Announces Pricing of its Public Offering". Lexington, MA & Amsterdam....
[6] Uniqure N.V.. (9/4/19). "Press Release: Uniqure Announces Proposed Public Offering". Lexington, MA & Amsterdam....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]